Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

ValiRx PLC (VAL)

  Print      Mail a friend       Annual reports

Friday 09 February, 2018

ValiRx PLC

Issue of options and directors dealings

RNS Number : 4699E
ValiRx PLC
09 February 2018
 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

Issue of options and directors dealings

 

London, UK., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management.  The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.

 

Name of Director

Number of Existing Options*

Option Award

Total number of Options

% of existing share capital

Oliver de Giorgio-Miller

555,000

2,750,000

3,305,000

0.8%

Dr Satu Vainikka

694,000

3,625,000

4,319,000

1.1%

Dr George Morris

597,000

3,125,000

3,722,000

0.9%

Gerry Desler

592,960

3,000,000

3,592,960

0.9%

Kevin Alexander

545,000

2,500,000

3,045,000

0.7%

Others

429,000

2,300,000

2,279,000

0.6%

Total

3,412,960

17,300,000

20,712,960

5.0%

*existing options are exercisable at a price between 43.125p - 125p

The issued share capital of the Company comprises 407,462,717 ordinary shares of 0.1 pence per shares. The table below illustrates the existing equity holdings of the directors:

Name of Director

Total number of shares

% of existing share capital

Oliver de Giorgio-Miller

59,555

0.015%

Dr Satu Vainikka

624,909

0.15%

Dr George Morris

588,287

0.14%

Gerry Desler

541,875

0.13%

Kevin Alexander

104,278

0.026%

Total

1,918,904

0.46%

 

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

[email protected]



Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray/Jo Turner/Richard Nash

Tel: +44 (0) 20 7213 0880



Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0) 207 382 8300

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Oliver de Giorgio-Miller

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

2,750,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

2,750,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr Satu Vainikka

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

3,625,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

3,625,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr George Morris

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

3,125,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

3,125,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Gerry Desler

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

3,000,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

3,000,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Kevin Alexander

2

Reason for notification


a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx Plc

b.

LEI

213800VQKB9SJCQDET40

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code


Options over ordinary shares

 

ISIN: GB00BWWYSP41

b.

Nature of the transaction

 Grant of options

c.

Price(s) and volume(s)







Price(s) per share

Volume(s)


4p

2,500,000


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

2,500,000

 

4p

e.

Date of the transaction

9 February 2018

f.

Place of the transaction

AIM

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAFANESSPEFF

a d v e r t i s e m e n t